Related Experiment Video

Updated: Mar 30, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.1K

Concomitant BET and MAPK blockade for effective treatment of ovarian cancer

Ying Jing1, Zhenfeng Zhang1,2, Pengfei Ma1

  • 1State Key Laboratory of Oncogenes and Related Genes, Renji-Med X Clinical Stem Cell Research Center, RenJi Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.

Oncotarget
|November 18, 2015
PubMed

Insights

Combining MEK and BET inhibitors effectively suppresses ovarian cancer cell growth and survival. This dual blockade targets apoptosis regulators, offering a promising therapeutic strategy for this lethal gynecologic malignancy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Ovarian cancer is a highly lethal gynecologic malignancy with limited treatment options.
  • Developing novel therapeutic strategies is crucial to improve patient survival rates.

Purpose of the Study:

  • To identify novel therapeutic targets for ovarian cancer.
  • To evaluate the efficacy of combining BET and MEK inhibitors in ovarian cancer treatment.

Main Methods:

  • A high-content image-based screen of 180 small molecule inhibitors was conducted.
  • Ovarian cancer cell lines were treated with BET inhibitors, MEK inhibitors, or a combination thereof.
  • Synergistic effects on apoptosis regulators were analyzed.

Main Results:

  • BET and MEK inhibitors demonstrated significant inhibition of ovarian cancer cell growth.
  • Combined MEK and BET inhibition was more effective than single-agent therapy, suppressing proliferation and survival.
  • Synergistic effects were observed on apoptosis regulators, including BIM and BAD.

Conclusions:

  • Concomitant blockade of BET and MAPK pathways represents a potent therapeutic strategy for ovarian cancer.
  • The combination therapy enhances apoptosis, leading to improved efficacy.
  • This approach holds promise for ameliorating patient outcomes in ovarian cancer.
Keywords:
BET inhibitorsMEK inhibitorsapoptosisovarian cancertargeted therapy

More Related Videos

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

12.9K
Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-107:59

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Published on: December 5, 2020

3.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K